Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Wednesday, February 24, 2010

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer - abstract

Conclusion: Pertuzumab may add activity to gemcitabine for the treatment of platinum-resistant ovarian cancer. Low HER3 mRNA expression may predict pertuzumab clinical benefit and be a valuable prognostic marker.

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.